39 Results for "

CPDs

" in MedChemExpress (MCE) Product Catalog:
Products (39)

39 Results for "CPDs" in MCE Product Catalog:

1
1 Cited Publications
Cat. No.: HY-168660
CAS No.: 3055471-57-0
Target:  

PROTACs Apoptosis CDK

Research Areas:  

Cancer

CPD-10 is a potent CCND1 and CDK4 PROTAC degrader. CPD-10 exhibits anti-proliferative effects on tumor cells and can also induce apoptosis. CPD-10 can be used for the study of breast cancer and lung cancer .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-158009
CAS No.: 6638-82-0
Purity:  ≥98.0%
Research Areas:  

Cancer

SGF29-IN-1 (Compound Cpd_DC60) is a selective inhibitor for Spt-Ada-Gcn5 acetyltransferase (SAGA)–associated factor 29 (SGF29)-Tudor domain. SGF29-IN-1 exhibits activity against leukemia .
loading...
    loading...
Cat. No.: HY-153386
CAS No.: 2891620-68-9
Purity:  99.83%
Research Areas:  

Cancer

CPD-1224 is an orally effective ALK inhibitor, a derivative of an ALK inhibitor that connects to the cereblon ligand. CPD-1224 targets the EML4-ALK oncogenic fusion protein and degrades both ALK and the mutant forms L1196M/G1202R. CPD-1224 can slow down tumor growth .
loading...
    loading...
Cat. No.: HY-112338
CAS No.: 823828-18-8
Purity:  98.29%
Synonyms: CPD188
Target:  

STAT Apoptosis

Research Areas:  

Cancer

C188 (CPD188) is a STAT3 inhibitor with anticancer effects. C188 inhibits STAT3 SH2/pY-peptide binding (IC50 of 20 µM against pY-peptide binding) and IL-6-mediated STAT3 phosphorylation. C188 is selective for STAT3 over STAT1. C188 inhibits nuclear-to-cytoplasmic translocation of Stat3. C188 shows highly active induces apoptosis in breast cancer cell lines with constitutive Stat3 activation (EC50s of 0.73 µM, 3.96 µM, and 7.01 µM in MDA-MB-468, MDA-MB-231, and MDA-MB-435 cultures, respectively) .
loading...
    loading...
Cat. No.: HY-P990114

Target:  

PD-1/PD-L1

Research Areas:  

Others

Anti-Canine PD-L1/B7-H1 Antibody (JC071) is an anti-canine PD-L1/B7-H1 IgG1 monoclonal antibody. Anti-Canine PD-L1/B7-H1 Antibody (JC071) can specifically bind to CHO-PDL1 cells and K562-cCD20-cPD-L1 cells. Anti-Canine PD-L1/B7-H1 Antibody (JC071) can enhance the level of IFN-γ. Anti-Canine PD-L1/B7-H1 Antibody (JC071) is often used in western blot experiments .
loading...
    loading...
Cat. No.: HY-168664
CAS No.: 3055472-38-0
Target:  

PROTACs CDK

Research Areas:  

Cancer

CPD-39 is a potent and orally active CCND1 and CDK4 heterobifunctional PROTAC degrader. CPD-39 shows anti-proliferation .
loading...
    loading...
Cat. No.: HY-P99641
CAS No.: 1808081-43-7

Research Areas:  

Cancer

Gilvetmab is a canine-derived anti-cPD-1 monoclonal antibody, as well as an immune activator/antitumor agent. Gilvetmab binds to canine PD-1, blocks the interaction of PD-1/PD-L1/L2, prevents immunosuppression, reactivates antitumor responses, induces tumor regression or disease stabilization, and may also trigger pseudoprogression. Gilvetmab can be used in research related to malignant melanoma and mast cell tumors .
loading...
    loading...
Cat. No.: HY-22391
CAS No.: 99733-18-3
Synonyms: tert-Butyl 2,8-diaminooctanoate
Target:  

PROTAC Linkers

Research Areas:  

Cancer

tert-Butyl (7-aminoheptyl)carbamate (tert-Butyl 2,8-diaminooctanoate) is a PROTAC linker. tert-Butyl (7-aminoheptyl)carbamate can be used to synthesis CPD-10 (HY-168660) .
loading...
    loading...
Cat. No.: HY-143498
CAS No.: 2411584-25-1
Target:  

DNA/RNA Synthesis

Research Areas:  

Cancer

ERCC1-XPF-IN-1 is a potent and high-affinity ERCC1-XPF inhibitor with IC50 value of 0.49 μM. ERCC1-XPF-IN-1 has the capacity to potentiate the cytotoxicity effect of UV radiation and inhibiting DAN repair, by the inhibition of removal of CPDs, and cyclophosphamide toxicity to colorectal cancer cells .
loading...
    loading...
Cat. No.: HY-163705
Target:  

PROTACs FGFR

Research Areas:  

Cancer

BR-cpd7 is an orally active, selective PROTAC degrader targeting FGFR1 and FGFR2, with a DC50 of 2.2 nM against FGFR1. BR-cpd7 reduces FGFR signaling. BR-cpd7 induces cell cycle arrest and selectively blocks the proliferation of FGFR1/FGFR2-dependent tumor cells. BR-cpd7 exhibits significant antitumor efficacy in FGFR1-dependent lung cancer animal models, while achieving complete depletion of FGFR1. BR-cpd7 can be used for cancer-related research .
loading...
    loading...
Cat. No.: HY-174416
CAS No.: 1824647-09-7
Target:  

E1/E2/E3 Enzyme

Research Areas:  

Cardiovascular Disease

Smurf1-IN-5 (Compound cpd-6) is an allosteric SMAD ubiquitin regulatory factor 1 (SMURF1) inhibitor. Smurf1-IN-5 leads to a reduction in the ubiquitylation of substrates such as BMPR2 (bone morphogenetic protein receptor 2) and SMAD1, enhancing the BMP (bone morphogenetic protein) signaling pathway. Smurf1-IN-5 is promising for research of pulmonary arterial hypertension (PAH) .
loading...
    loading...
Cat. No.: HY-147310
CAS No.: 2573912-32-8
Purity:  98.07%
Research Areas:  

Infection

CU-CPD107 is a potent, selective toll-like receptor 8 (TLR 8) agonist. CU-CPD107 inhibits TLR8 signaling. CU-CPD107 converts to synergistic agonist activities in the presence of ssRNA and induces TLR8 signaling. CU-CPD107 inhibits proinflammatory factor expression and avoids immune responses in the presence of ssRNA .
loading...
    loading...
Cat. No.: HY-174991
Target:  

IRE1

Research Areas:  

Neurological Disease Cancer

CPD-2828 is an orally active and selective IRE1α inhibitor with an IC50 value of 1.2 μM. CPD-2828 is promising for research of endoplasmic reticulum stress-related diseases (e.g., cancer, neurodegenerative diseases) .
loading...
    loading...
Cat. No.: HY-161606
CAS No.: 3034665-49-8
Target:  

PARP

Research Areas:  

Cancer

PARP-1/2/7-IN-1 (compound 86) is a potent inhibitor of PARP-1/2/7, with the IC50 of < 10 nM .
loading...
    loading...
Cat. No.: HY-161607
CAS No.: 3034666-02-6
Target:  

PARP

Research Areas:  

Cancer

PARP7-IN-21 (compound 128) is a potent inhibitor of PARP7, with the IC50 of < 10 nM .
loading...
    loading...
Cat. No.: HY-N7893
CAS No.: 83459-37-4
Ebracteolata cpd B is a natural phenol compound found in Euphorbia ebracteolata .
loading...
    loading...
Cat. No.: HY-176927
CAS No.: 3031725-06-8
Research Areas:  

Cancer

ADC-VI (Compound 6) is a conjugate of a toxic molecule and a linker, in which the cytotoxin carried by CPD6 is Deruxtecan (HY-13631E). Tricyclene is used to form an antibody-drug conjugate (ADC) by a chemical conjugation reaction through linking with an anti-FGFR2b antibody .
loading...
    loading...
Cat. No.: HY-171786
CAS No.: 2928619-86-5
Target:  

CDK

Research Areas:  

Cancer

CDK12-IN-8 (Compound Cpd143) is an orally active and highly selective inhibitor of cyclin-dependent kinase 12 (CDK12). CDK12-IN-8 inhibits CDK12-mediated phosphorylation of the C-terminal domain (CTD) serine 2 of RNA polymerase II, interfering with gene transcription elongation and DNA damage repair pathways. CDK12-IN-8 is promising for research of cancers with high CDK12 expression such as small cell lung cancer and triple-negative breast cancer .
loading...
    loading...
Cat. No.: HY-168662
CAS No.: 2139329-57-8
Research Areas:  

Cancer

Palbociclib-CH2COOH is a Ligands for Target Protein for PROTACs. Palbociclib-CH2COOH can serve as an active control for the target protein ligand of CPD-39 (HY-168664) and CPD-10 (HY-168660) .
loading...
    loading...
Cat. No.: HY-144028
CAS No.: 2583778-77-0
Target:  

Trk Receptor

Research Areas:  

Cancer

Compound cpd-1 is a small molecule Trks inhibitor with good antitumor activity .
loading...
    loading...